On December 27, 2017 LIDDS reported that it has successfully completed the first steps in one of its projects assessing the feasibility of using the NanoZolid drug delivery technology for intratumoral immunotherapy with positive results (Press release, Lidds, DEC 27, 2017, View Source [SID1234555921]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In one of LIDDS immune-oncology projects, an immune-stimulatory agent was successfully formulated using the NanoZolid drug delivery technology. Chemical analytical methods demonstrated that the agent had a very promising release profile from the drug formulation. In a second step, the NanoZolid formulated immune-stimulatory agent was tested in an immuno-oncology model of a aggressive/hard to treat cancer in mice. In this model, a single dose of the locally delivered immunotherapy significantly reduced tumour growth and increased survival in the treated animals compared to control animals.
This demonstrates that that the NanoZolid drug delivery technology can be leveraged to develop novel immunotherapies that can act locally or intratumorally.
A locally delivered immunotherapy has the potential to act either as a monotherapy or in combination with systemic immunotherapies e.g. checkpoint inhibitors. A successful combination treatment could significantly increase the response rates and efficacy rates of current immunotherapies.
A recent review article in the highly ranked journal Annals of Oncology (Impact Factor 11.855) highlights the unique opportunity of intratumoral treatments to increase the efficacy of immunotherapy while reducing the potential side-effects.
Results from the other preclinical feasibility studies are expected in the first quarter of 2018.
Immunotherapy for the treatment of cancer aims to activate and utilize the body’s own immune system to recognize and attack tumors and cancer cells and is today the fastest growing and most promising area of cancer research.